Gainers:
Goldman Sachs Group, Inc. (GS) is up 0.56 percent to $125.20. The company swung to a profit in its third quarter and its earnings per share topped Wall Street view. The company also increased its quarterly dividend.
Mattel, Inc. (MAT) is gaining nearly 5 percent to $37.05. The company's third quarter profit and sales improved from the year-ago quarter and were above Wall Street view.
Johnson & Johnson (JNJ) is up 1 percent to $69.40. The company's third quarter profit slipped from the year-ago quarter, but its adjusted earnings per share topped analysts' estimate. Sales to customers improved 6.5 percent.
UnitedHealth Group Inc. (UNH) is rising over 1 percent to $58.24. The company's third quarter earnings improved from the prior year period and also topped analysts' projection. Total revenues improved from the year-ago quarter, but marginally missed the consensus estimate. Meanwhile, the company raised its earnings outlook for 2012.
Domino's Pizza, Inc. (DPZ) is up nearly 4 percent to $39.67. The company's third quarter earnings and sales increased from the year-ago quarter and were above Wall Street view.
Decliners:
Citigroup Inc. (C) is falling over 2 percent to $35.89 following its announcement that Vikram Pandit has stepped down as its chief executive Officer and as a member of the board, effective immediately. The company's board has unanimously elected Michael Corbat as CEO and a director. The company further announced that its president and chief operating officer, John Havens, has resigned.
Clearwire Corp. (CLWR) is down 16 percent to $2.25 amidst reports that Sprint Nextel Corp. (S), which announced a deal to sell 70 percent stake to Japan's Softbank Corp., has no immediate plans to take over the Bellevue, Washington-based company.
Wolverine World Wide, Inc. (WWW) is falling more than 3 percent to $41.87. The company's third quarter profit and revenue declined from the previous year period.
Trading halt:
Trading in shares of NPS Pharmaceuticals, Inc. (NPSP) was halted. The FDA's Gastrointestinal Drugs Advisory Committee is meeting today to review Gattex (teduglutide), a recombinant analog of human glucagon-like peptide 2 being developed for the treatment of adults with short bowel syndrome.
For comments and feedback: editorial@rttnews.com